Table 4 Oncologic and demographic characteristics of patients who showed increment in nadir PSA
From: Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy
Variable | N, percentage (%) |
|---|---|
Patients (n, %) | 15/50 (30%) |
Age (years) (mean ± SD, range) | 69.04 ± 10.42 (52–89) |
Gleason score (median, range) | 8 (6–9) |
Metastasis (n, %) | |
Bone | 10 (66.67%) |
Lymph node | 4 (26.67%) |
Lung | 1 (6.66%) |
Pre-therapeutic PSA (ng/ml) (median, range) | 84.5 (20–1201) |
Nadir PSA (ng/ml) (median, range) | 2.5 (0.09–50) |
Time to nadir PSA (month) (mean ± SD, range) | 4.12 ± 1.75 (1–7) |
Cores involved (n) (mean ± SD, range) | 4.96 ± 2.27 (1–10) |
Percentage of cores involved (mean ± SD, range) | 70.87 ± 24.68 (12.5–100) |
PSA at last follow-up (ng/ml) (median, range) | 5.7 (1.1–85) |
Follow-up (month) (mean ± SD, range) | 13.69 + 6.26 (4–30) |